Journal
ACTA PHARMACEUTICA SINICA B
Volume 12, Issue 2, Pages 774-786Publisher
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.05.019
Keywords
Glioblastoma; Brain metastasis; PI3K-mTOR-AKT signaling pathway; PI3K inhibitor; IL-17A
Categories
Funding
- CAMS Innovation Fund (China) [2016-I2M-3-008]
- Drug Innovation Major Project (China) [2018ZX09711001-003-011, 2018ZX09711001-005-017]
- Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences (China) [2018PT35003]
Ask authors/readers for more resources
XH30, a potent PI3K inhibitor, exhibits anti-tumor activity against human glioblastoma by inhibiting cell proliferation, blocking PI3K pathway activation, and suppressing tumor cell migration.
Glioblastoma is carcinogenesis of glial cells in central nervous system and has the highest incidence among primary brain tumors. Brain metastasis, such as breast cancer and lung cancer, also leads to high mortality. The available medicines are limited due to blood-brain barrier. Abnormal activation of phosphatidylinositol 3-kinases (PI3K) signaling pathway is prevalent in glioblastoma and metastatic tumors. Here, we characterized a 2-amino-4-methylquinazoline derivative XH30 as a potent PI3K inhibitor with excellent anti-tumor activity against human glioblastoma. XH30 significantly repressed the proliferation of various brain cancer cells and decreased the phosphorylation of key proteins of PI3K signaling pathway, induced cell cycle arrest in G1 phase as well. Additionally, XH30 inhibited the migration of glioma cells and blocked the activation of PI3K pathway by interleukin-17A (IL-17A), which increased the migration of U87MG. Oral administration of XH30 significantly suppressed the tumor growth in both subcutaneous and orthotopic tumor models. XH30 also repressed tumor growth in brain metastasis models of lung cancers. Moreover, XH30 reduced IL-17A and its receptor IL-17RA in vivo. These results indicate that XH30 might be a potential therapeutic drug candidate for glioblastoma migration and brain metastasis. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available